The symptoms that don't add up

The knees that start complaining on a walk you've done for years. The headache that arrives on a Tuesday with no obvious cause. The shoulder that aches through the night after nothing more strenuous than a day at a desk. For many women in their mid-forties, these complaints accumulate quietly — each one easy to dismiss, but harder to ignore when they all arrive together.

The instinctive explanation is ageing. Yet something about that answer feels incomplete, especially when the shift happens faster than expected, and when no injury, no illness, and no obvious lifestyle change accounts for it.

Joint aches, muscle soreness, and worsening headaches are among the most commonly reported — and least explained — symptoms of perimenopause, a transition that can begin a full decade before periods stop. Many women encounter it without ever connecting the dots to hormones.

These symptoms are not random. They share a single upstream cause, and it sits squarely in the Chemistry pillar of the Regen PhD framework: the body's internal environment is changing, and pain is one of the earliest signals.

Why oestrogen's fall is anything but gradual

Oestrogen is less a reproductive hormone than a body-wide regulatory signal. Receptors for it sit in joint cartilage, immune cells, brain tissue, gut lining, and blood-vessel walls — virtually every cell type carries them. That near-universal distribution means that when supply becomes unreliable, the consequences extend far beyond reproductive function.

What makes perimenopause particularly disruptive is the pattern of the change. Rather than a steady, manageable descent, oestrogen levels spike and plummet erratically — sometimes week to week — across a window that may span a decade before periods cease altogether. Progesterone, which declines concurrently, normally provides its own calming counterbalance; its retreat amplifies the turbulence. The body is not adapting to a new set-point; it is navigating repeated, unpredictable swings in its internal chemistry.

In the Regeneration by Design framework developed by Professor Paul Lee, this is a Chemistry-pillar event: the body's internal environment — hormones, inflammation, cellular signalling — is being destabilised at a foundational level. The four pillars are interdependent, so instability in Chemistry ripples outward. Not every woman will experience severe symptoms; the range is wide. But the biology of receptor ubiquity means that even modest hormonal turbulence has the potential to affect multiple systems at once — which is why the downstream effects, explored in the sections that follow, turn out to be so varied and so easy to misread.

How oestrogen normally holds inflammation in check

Think of oestrogen as a dimmer switch on the body's inflammatory circuitry. Its most important molecular target is NF-κB — a transcription factor that acts as a master on-switch for pro-inflammatory gene expression. When NF-κB is activated, it instructs immune cells to produce a cascade of signalling proteins. Oestrogen, acting through the p38 MAPK/NF-κB cascade, keeps that switch dialled down, directly suppressing the release of macrophage-derived cytokines including IL-6 and TNF-α. The mechanism is well-characterised in cell and animal studies, and while large perimenopausal-specific trials are fewer, the foundational science is robust.

Macrophages — the immune system's first-responder cells — are particularly sensitive to this hormonal regulation. When oestrogen is present at adequate levels, macrophages tend toward a repair-oriented, anti-inflammatory state. As it falls, they can shift toward a pro-inflammatory profile, releasing cytokines that drive tissue irritation rather than tissue recovery. The brake, in effect, is easing off at precisely the moment the body most needs it.

A second mechanism compounds this. Declining oestrogen promotes a redistribution of body fat toward the visceral (abdominal) compartment. Visceral fat is not metabolically inert; it actively secretes its own inflammatory mediators, adding a secondary chemical signal on top of the hormonal one.

Professor Paul Lee frames this in Practical Regeneration as a double hit: oestrogen's loss both removes the anti-inflammatory brake and heightens pain-receptor sensitivity simultaneously. The result is a body that is more inflamed and more reactive to that inflammation — not because something has gone wrong in isolation, but because a single regulatory molecule was doing two jobs at once.

What the research says about pain in perimenopause

Clinical research has begun to put precise numbers on what many women experience as inexplicable pain. Three converging lines of evidence make the picture increasingly hard to dismiss as coincidence.

A 2025 review examined how oestrogen levels affect knee osteoarthritis pain during perimenopause and found that the hormone appears to modulate pain through three simultaneous pathways — regulating inflammatory responses, inhibiting cellular senescence and apoptosis in joint tissue, and modulating neurotransmitter systems. All three are degraded in tandem as oestrogen falls. That overlap may help explain why joint pain in midlife can feel qualitatively different from earlier injuries: more persistent, more diffuse, less responsive to the usual remedies.

Central pain sensitivity, not just local joint chemistry, also appears measurably altered. A 2026 study in women with temporomandibular disorder found that those in menopause without hormone therapy had significantly lower pressure pain thresholds and impaired conditioned pain modulation compared to women with regular menstrual cycles. Conditioned pain modulation is the nervous system's capacity to dampen one pain signal in the presence of another — an internal braking mechanism. Its impairment suggests the changes extend beyond individual joints to how the brain processes pain globally.

Migraine data adds a third dimension. A 2025 analysis found that pain intensity, attack duration, and the number of headache days per month were all significantly higher during perimenopause than in reproductive-age women, with musculoskeletal disease risk also elevated (odds ratio 4.25).

These are largely observational findings, and cleanly separating hormonal effects from concurrent ageing remains methodologically difficult. But collectively they describe a recognisable, documented pattern: perimenopausal pain is not random or purely subjective. It carries measurable biological signatures — which, in the Regeneration by Design framework, is the starting point for doing something about it.

Why the storm is bigger than oestrogen alone

Oestrogen is central to this story, but it does not carry the chemistry storm alone. Two further forces amplify the disruption.

Progesterone declines alongside oestrogen during perimenopause and normally contributes its own calming and anti-inflammatory buffering. Where oestrogen acts on the immune system's master switches, progesterone tends to quieten the stress response and moderate inflammatory signalling in its own right. Its concurrent loss means the body loses two complementary brakes simultaneously rather than one.

Layered on top is what researchers call inflammaging — the slow background hum of immune activity that tends to rise with age independently of hormones. As the innate immune system becomes progressively less well-regulated over time, chronic low-grade inflammation accumulates even without infection or injury. In midlife, this age-related drift meets the hormonal transition head-on, compounding rather than simply adding to it.

A third complication involves oestrogen's role in muscle repair. Research suggests it operates within a 'Goldilocks zone': at normal female levels, oestrogen helps calibrate the inflammatory signal that initiates tissue recovery after exercise. Too little, and that signal is blunted — muscles repair less efficiently, and the cumulative cost of everyday physical activity quietly rises.

This is precisely the picture that Regeneration by Design is structured to address. Professor Paul Lee's argument is that the four pillars do not fail in isolation — when Chemistry is destabilised, Physics and Biology feel the pull too. Recognising the storm as a convergence, not a single cause, is what makes it possible to navigate rather than merely endure.

What you can actually do about it

Each of the steps below has a specific upstream target, not a general health benefit.

Exercise: keeping the repair signal alive. Without sufficient oestrogen, the inflammatory signal that normally initiates muscle and tissue repair after exertion is blunted — what researchers describe as losing the Goldilocks zone for post-damage recovery. Structured resistance training two to three times weekly, alongside moderate aerobic work, may help sustain the physical stimulus for tissue remodelling when the hormonal one has weakened. Aerobic exercise also appears to attenuate circulating IL-6 and TNF-α over time — the same cytokines that the NF-κB pathway normally restrains. Physics and Chemistry, working in parallel.

Nutrition: the NF-κB pathway has a dietary lever. The inflammatory cascade that oestrogen normally keeps dialled down responds to dietary inputs too. Omega-3-rich foods, polyphenol-dense vegetables, and broadly Mediterranean-style eating patterns have consistent evidence for moderating cytokine production via overlapping anti-inflammatory pathways. This is the Chemistry pillar's most accessible daily adjustment.

Sleep: the hidden cost of the inflammatory loop. Poor sleep independently raises circulating inflammatory markers and cortisol levels, compounding an already-reduced anti-inflammatory buffering capacity. Seven to nine hours of quality sleep is not a wellness routine — it is direct management of total inflammatory load.

Monitoring: making the chemistry visible. The Regen PhD Biomarker Panel is designed to give a chemistry baseline across 32 markers, including inflammation and recovery indicators that directly reflect the cellular activity described above — the cytokine signals that oestrogen normally keeps in check. Tracking these over time turns lifestyle adjustments from approximation into evidence, and gives a practical reference point for conversations with a GP or specialist about what is actually shifting. For significant or distressing symptoms, that conversation is the right first step, not the last resort.

Professor Paul Lee's argument across Regeneration by Design and Practical Regeneration is that systemic change starts with systemic awareness — knowing your chemistry baseline is what separates actively designing your healthspan from simply waiting for the storm to pass.

1. [1] Oestrogen exerts anti-inflammation via p38 MAPK/NF-κB cascade in adipocytes. (2016). https://doi.org/10.1016/j.orcp.2016.02.007 https://doi.org/10.1016/j.orcp.2016.02.007
2. [2] The Mechanism by Which Estrogen Level Affects Knee Osteoarthritis Pain in Perimenopause and Non-Pharmacological Measures. (2025). https://doi.org/10.3390/ijms26062391 https://doi.org/10.3390/ijms26062391
3. [3] Psychophysical pain measures in women with painful TMD across menopausal status and hormone therapy use. (2026). https://doi.org/10.1080/08869634.2026.2649364 https://doi.org/10.1080/08869634.2026.2649364
4. [4] Analysis of the migraine characteristics in the perimenopause. (2025). https://doi.org/10.14412/2074-2711-2025-1-16-23 https://doi.org/10.14412/2074-2711-2025-1-16-23
5. [5] Physiotherapy in perimenopause: Prevention, rehabilitation, and post-rehabilitation. (2025). https://doi.org/10.5937/erhs4-64176 https://doi.org/10.5937/erhs4-64176
6. [6] Inflammaging. https://en.wikipedia.org/?curid=59830296 https://en.wikipedia.org/?curid=59830296
7. [7] Oestrogen and a Goldilocks zone for post-damage muscle inflammation and repair?. (2018). https://doi.org/10.1113/JP276870 https://doi.org/10.1113/JP276870